Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It appears that the upload to OTC Markets was not completed accurately. It has been corrected and should be reflected tomorrow.
Thanks!
Regards,
securedownload
Operations Manager
Transfer Online, Inc.
thank you, I'll take em.
Offering price has been arbitrarily determined by the Board of Directors......... at .25$
Highlights from database studies performed by technical advisors Tetra Tech Inc. include:
Newly identified areas demonstrate the potential to host additional high-grade mineralization.
Skarn hosted mineralization has similarities to a recent discovery in the area.
Fault kinematic study highlights additional targets.
Additional untested geophysical targets identified.
Geochemical assessment of historical drilling data expands mineralization understanding.
New 3D geological and mineralization model generation.
In advance of restarting drilling and exploration activities on the Property, Silver Dollar requested that Tetra Tech conduct comprehensive desktop studies of La Joya's extensive historical database to identify additional areas of opportunity that exist on the Property. These studies included a detailed review of historical geophysical, geochemical, and regional exploration data, and detailed comparisons to nearby properties. Silver Dollar is pleased to report these studies have successfully identified several new highly prospective regions with the potential to host additional high-grade mineralization at La Joya. Findings of the various studies are summarized below:
Thanks Spark.. added to the pile.. someday people will pay attention..
Market Cap
756,388
02/01/2021
pay attention to the unrestricted number as well as the date it was verified,, the float will never be over that but may be more than is labeled.
verified three weeks ago, close enough
Unrestricted 25,200,722 01/08/2021
phone call to transfer agent but she left for the day, I sent her an email she should get back to me by market open.
something is wacked.
that was off topic but I will respond.. that holding not my kind of play
Market Cap 32,856,289 01/29/2021
Authorized Shares 2,490,000,000
02/01/2021
I work that out to be a 1.2 million market cap, that's like a bowl of peanuts in a wine cellar full of 10 year old Merlot.
This one will be fun to watch, when it goes there will be dozens claiming they found it first, you very well know how that works.
Once the story is secure I will put this on do not disturb for a year and not even look at it.
Market Cap 1,200,000 01/29/2021 Really, I have seen defunct shells with a 10 million market cap, it will go but it needs patience.
Hello 100% success rate on covid 19
Ah this thing is going parabolic once the news sinks in, expect to see professional money followed by a buy out... good lord, it is a market cap of 7 milly and it could I said could be a 100 million market cap company, that would put the price per share at $2.11 if there is no dilution.
Hello 100% success rate on covid 19
QNTA
Quanta, Inc.
Common Stock
0.13
-0.0199
-13.28%
0.12 / 0.13 (1 x 1)
QNTA Security Details
Share Structure
Market Cap Market Cap
7,088,317
01/29/2021
Authorized Shares
500,000,000
01/08/2021
Outstanding Shares
47,286,970
01/08/2021
Restricted
22,086,248
01/08/2021
Unrestricted
25,200,722
01/08/2021
Held at DTC
Not Available
Float
10,190,900
11/25/2019
Par Value
No Par Value
Newsfile Corp.
Mon, February 1, 2021, 5:30 AM
DTC eligibility simplifies the process of trading and transferring the Company's common shares between brokerages in the United States
Vancouver, British Columbia--(Newsfile Corp. - February 1, 2021) - Silver Dollar Resources Inc. (CSE: SLV) (OTCQB: SLVDF) ("Silver Dollar" or the "Company") is pleased to announce that its common shares are now eligible for settlement through the Depository Trust Company ("DTC"), a subsidiary of the Depository Trust & Clearing Corp. that manages the electronic clearing and settlement of publicly-traded companies in the United States.
Silver Dollar's common shares are now fully DTC eligible and will continue to trade in the United States under the ticker symbol "SLVDF" on the OTCQB Venture Market. Through an electronic method of clearing securities, DTC eligibility reduces costs and accelerates the settlement process for investors and brokers allowing the Company's common shares to be traded over a much wider selection of brokerage firms by coming into compliance with their requirements.
"DTC eligibility is an important step in the maturity of Silver Dollar and our ongoing efforts to present the Company to a broader audience of potential investors," said Mike Romanik president of Silver Dollar. "Our common shares are now more accessible to retail and institutional investors in one of the largest markets in the world, and all our shareholders should benefit from the expected increase in trading liquidity."
About Silver Dollar Resources Inc.
Silver Dollar Resources Inc. is a mineral exploration company focused on creating shareholder value by finding and developing economic precious and base metal deposits. Having completed its initial public offering in May 2020, the Company trades on the Canadian Securities Exchange under the symbol "SLV" and on the OTCQB under "SLVDF". Silver Dollar's projects are located in two of the prolific mining jurisdictions in the world and include the advanced exploration and development stage La Joya Silver Project in Durango, Mexico, and the discovery-stage Pakwash Lake and the Longlegged Lake properties in the Red Lake Mining District of Ontario, Canada. The Company has an aggressive growth strategy and is actively reviewing projects in mining-friendly jurisdictions internationally for potential acquisition.
For additional information: Contact investor relations, you can download our latest presentation by clicking here and you can follow us on Twitter by clicking here.
Joseph Cullen,
Investor Relations Manager
Direct line: (778) 919-8615
Email: joseph@silverdollarresources.com
Also lets realize a NI 43-101 is done by a qualified licensed geologist. The report depicts value present and future and is the basis for funding. What is under the ground, how long is the mine life and what is the length of time to payback are all answered in the 43-101
Gosh I don't know Mick, these reverse merger plays can run so quickly that using that system may be good for an entry but when it happens it happens big and without notice.
This is the low, you may get some bid sitting but at this price the ask is a gift. Do not rely on charts too much, this stock will be story driven and make sure the seat belt is fastened when (and if) it does.
That is a safe mid term target.
Page 8 will give you the historical drill results.. impressive even with a high cutoff
https://silverdollarresources.com/images/Silver-Dollar_Presentation.pdf
Confirmed presence of high-grade mineralization with 2014 highest assay grades reported for Ag of 1,915 grams per tonne (gpt) over 0.45 metre(hole LJ DD14-116 from 26.4 to 26.85 m), Cu of 20.4 % over 0.55 metre (hole LJ DD14-116 from 86 to 86.55 m), and Au of 33.5 gpt over 1.0 metre (hole LF DD14-120 from 211.15 to 212.15 m),?Presence of discrete high-grade stockwork and structurally controlled veining (SCSV) style mineralization such as in hole LJ DD14-116 that intercepted 2.0 metres (from 86 to 88 m) grading 723.5 gpt Ag, 8.97 % Cu and 0.09 gpt Au, or 1,778.1 gpt silver equivalent (AgEq),
?Continuous broad intervals of mineralization hosted in replacement manto style mineralization, such as in hole LJ DD14-114 that intercepted 66.4 metres (from 27.1 to 93.5 m) grading 43.5 gpt Ag, 0.27 % Cu and 0.38 gpt Au, or 98.21 gpt AgEq, and?Outcropping and near-surface mineralization, such as in holes LJ DD14-109 that intercepted 21.92 metres (from 1.8 to 23.72 m) grading 31.5 gpt Ag, 0.36 % Cu and 0.95 gpt Au, or 130.4 gpt AgEq
This is the historical mineral estimate of the property.
It will have to be updated to achieve the proper funding.
Key assumptions, parameters, and methods used to prepare the historical mineral estimate:
1) 89 holes totaling 30,085 metres (m).
2) Raw assay data was composited to 2 metres, capped at 550 gptAg, 5.5 gptAu 6% Cu and interpolated into a block model using 5 m x 5 m x 5 m block size using inverse distance squared (ID2) methodology.3) Silver equivalency formula assumes Ag:Auis 50:1, Ag:Cuis 86:1, based on US$24/oz silver, US$1200/oz gold, US$3/lb copper and 100% metallurgical recovery.4) Mining by open-pit methods.5) Mining and process costs assumptions not specifically stated.
I held off buying until 1.24 and 1.19, we are past that dip and I doubt it will return that low.
This should be the last of the toe rag investors just getting out of this stock from an awareness program.
At this point anything under 1.50 is a steal but as the future gets closer I have no problem paying $2 or $3 dollars per share here if the story shows promise.
This entire story depends on the NI43-101 and the size and scope of the drill program, that is what I need to see before I toss 5 figures into this as a long term hold, however under the counter whispers are saying this is a major blowout discovery..
I consider this price to be undervalued for what we have here.
We shall see.
Insiders own ~41% of shares issued including First Majestic Silver and Eric Sprott5** Includes 1,500,001 Escrow shares
Insidersholdings: ~41% of shares issued including:First Majestic Silver Corp. holding ~16% and Co-founding shareholder Eric Sprott holding
~17%Shares Issued** 36,822,734Warrants 5,575,028
Stock Options3,400,000 Fully-Diluted45,797,76252
-Week High/Low$2.29 / $0.22 30-Day Average Trading Volume316,91430-
Day Volume Weighted
Average Price$ 1.89January 15 Closing Price$ 1.73Market CapCAD$ ~64,000,000
Project overview
Corporate Highlights
4Quality projects, experienced people and good share structure
?$10.5 Million financing closed with lead orders from Eric Sprott and First Majestic Silver Corp.
?Latest drilling at La Joya returned significant mineralization in 15 of 17 holes including 1,778 g/t silver equivalent (62.7 oz/ton AgEq) over 2 metres in hole LJ DD14-116.
?Definitive Agreement signed to acquireup to a 100% interest in the La Joya Silver Project located in the State of Durango in the Mexican Silver Belt.
?Mine Finders Perry Durning and Frank (Bud) Hillemeyer, past recipients of the PDAC Thayer Lindsley Int’l. Mineral Discoveries Award, joined Silver Dollar as Technical Advisors.
?Prospecting, soil sampling and mapping, and IP surveying underway on Long legged Lake property in Red Lake to follow up on key structures identified in 2019 MAG survey.
?Northern boundary of Pakwash Lake property inRed Lake borders TNT Target, a potential Cu-Ag-Au VMS discovery being explored by BTU Metals.CSE: SLV |OTCQB: SLVDF | Frankfurt: 4KW
Mining plays are usually run on hope, but I doubt it will hit $30 per share until they are well into multi month production with good numbers.. even though silver will double in the next year or so profits on silver mines are iffy at best sometimes. However Sir Sproutt knows that and only invests in strong potential winners.
I am however.. pay attention here.. putting all r/m project profits into this company and one gold company.. this should really be completed by the end of Sept when the entire market changes and only accredited investors will be able to see and play any stock below pink current status.
I have known Eric Sprout personally for over 10 years and we once sat down for a lunch together... which really means diddly squat.
I see no reason to carve up the company. Raising money for all projects is easier with the size of the market cap that it would the company as a whole would represent.
There are some unknowns and that remains to be seen.. this is either going to be a multi national mining company with high grade assets or it could be just a pocket investment for a person who happens to be currently a CEO of a private company.
Big picture: the company is moving forward.. Little picture: snails pace of information;;
Looks like permitting and foundation layout are set.. at least they are off the to do list.
thanks for those, whoever got impatient.
Do you really think this would have happened .. given the research and fact finding institutions can do?
On January 12, 2021, Inspyr Therapeutics, Inc. (“Company”) sold $500,000 of senior convertible debentures (“Debenture”) for (i) $500,000 for cash to an existing institutional investor (the “Investor”) of the Company.
Bahh won't matter, the stock price is just an illusion right now until the National Instrument 43-101 is published.
that was and still is scheduled for 2nd quarter 2021.
Until I understand the size of the open pit and the overburden will I understand which quarter the revenues will start coming.
Everything else is just noise.
These will have a 6 month hold once issued.
Per the terms of the December 21, 2020 Securities Exchange Agreement with Medolife Rx, the Company shall acquire 51% of Medolife Rx in exchange for 9,000 shares of newly created Series B Convertible Preferred Stock, which, once issued to certain Medolife Rx designees upon closing, shall be convertible into fifty-four percent (54%) of the issued and outstanding shares of the Company’s common stock on a fully converted basis.
reverse merge last Dec. https://www.otcmarkets.com/filing/html?id=14589020&guid=V10KU679ctIb73h
you are correct, bid sitting never works anyway, you waste hours and get dribbles.. if you have done you homework you know that the ask is cheap!
short squeeze will not happen here, this stock is primarily a Canadian ticker with US add on hence the "F" in the ticker for foreign
When a major mineral mutual fund manager spends $6.5 million of his own money on a project you best pay attention!
QNTA NEWS::: More importantly, all COVID-19 healthcare workers, including physicians and nurses, who took Escozine as a preventative, never tested positive" said Dr. Khalid Matalka, another leading scientist at Medolife, specializing in Cancer Therapy and Immunology. "The clinical trial results indicate that Escozine could be used as monotherapy or in combination with standard therapies against COVID-19, which will accelerate the healing from the virus. Besides, observations revealed that Escozine could be used as prevention from the COVID-19 infection."
More importantly, all COVID-19 healthcare workers, including physicians and nurses, who took Escozine as a preventative, never tested positive" said Dr. Khalid Matalka, another leading scientist at Medolife, specializing in Cancer Therapy and Immunology. "The clinical trial results indicate that Escozine could be used as monotherapy or in combination with standard therapies against COVID-19, which will accelerate the healing from the virus. Besides, observations revealed that Escozine could be used as prevention from the COVID-19 infection."
QNTA: More importantly, all COVID-19 healthcare workers, including physicians and nurses, who took Escozine as a preventative, never tested positive" said Dr. Khalid Matalka, another leading scientist at Medolife, specializing in Cancer Therapy and Immunology. "The clinical trial results indicate that Escozine could be used as monotherapy or in combination with standard therapies against COVID-19, which will accelerate the healing from the virus. Besides, observations revealed that Escozine could be used as prevention from the COVID-19 infection."
Successful in Treating COVID-19 Patients
Medolife's Therapeutic Scorpion Peptide Proves Successful in Treating COVID-19 Patients in Dominican Republic Study
Updated Wed, January 27, 2021, 6:03 AM
BURBANK, CA / ACCESSWIRE / January 27, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA) today announced In a recent study, a total of 400 patients in the Dominican Republic - where, a majority tested positive for COVID-19, and a small portion were COVID-19 symptomatic even though they tested negative for COVID-19 - reported a 100 percent improvement in symptoms after being administered Escozine®. Many of the patients participating in the study reported severe COVID-19 symptoms, such as difficulty breathing, pain and high fever, which Escozine® was able to relieve within 5 days of treatment. Even patients under ventilators were discharged within days, thanks to this novel product. Located in Santo Domingo, Dominican Republic, The Cruz Jiminian Clinic has carried out this ongoing study since August 2020, and has reported 0 COVID-19 related deaths after the clinic began administering Escozine®. Escozine®, produced by Medolife Rx, Inc., ("Medolife"), is a therapeutic consisting of small molecule peptides derived from a specific species of scorpions, Rhopalurus princeps, endemic to the Dominican Republic. After the successful study, Escozine® is on fast-track to be registered with the Ministry of Health in the Dominican Republic in Q1 2021. Medolife also submitted the study data to the US FDA, which is currently under review for permission to repeat the clinical trial in the United States. In addition to supporting the recovery of COVID-19 patients, Escozine® was registered and certified for cancer treatment by the Ministry of Health in the Dominican Republic in 2010.
"The data proving the efficacy that Escozine has on a multitude of improved patient parameters is consistent with the rapid symptom relief I experienced while on site," said Dr. Annabelle Morgan, Cell and Developmental Biologist and one of Medolife's leading scientists. She noted, "What is even more astonishing is that 100% of patients tested negative for COVID-19 within 5-10 days of treatment."
"More importantly, all COVID-19 healthcare workers, including physicians and nurses, who took Escozine as a preventative, never tested positive" said Dr. Khalid Matalka, another leading scientist at Medolife, specializing in Cancer Therapy and Immunology. "The clinical trial results indicate that Escozine could be used as monotherapy or in combination with standard therapies against COVID-19, which will accelerate the healing from the virus. Besides, observations revealed that Escozine could be used as prevention from the COVID-19 infection."
Scorpion Venom Most Expensive Liquid in the World
From treating cancer to pain management to fighting viral infections, this unique peptide has a vast range of therapeutic applications. In the last decade, a growing interest from Big Pharma companies has caused an increase in the liquid's value: costing $39 million per gallon.
Medolife's Dominican Republic Scorpion Reservation is one of the largest breeding grounds for scorpions on earth. Combined with the company's more than 15 years of research, Medolife is positioned to continue developing groundbreaking formulas and pharmaceutical-grade medications for consumer use.
Pharma's Growing Interest in Scorpion Peptide-Based Therapeutics
Venom has been studied for therapeutic uses for decades. In 2015, the European FP7 Venomics Project studied over 200 animal species worldwide for venom-to-drug development.
Currently, six peptide drugs on the market are derived from venoms, and the pharmaceutical industry has demonstrated a growing interest in these naturally derived therapeutics. The first venom-derived drug, Captopril, was developed by Bristol-Myers Squibb. The drug, derived from snake venom, was approved for use in the 1980s to treat high blood pressure.
Snail venom was used in the development of Prialt®, which is used to treat pain. Also, Byetta®, used to treat type 2 diabetes, was derived from a lizard.
How Venom-Based Drugs Work
The Rhopalurus princeps venom contains a small molecular peptide that can pass through the blood-brain barrier in the body. Four small molecular peptides in the venom can attack various diseases in humans. To do this, it blocks small-conductance chloride, sodium, potassium and calcium ion channels, and it also binds preferentially to abnormal and cancerous cells, leaving the normal cells intact. Medolife holds exclusive rights to the Rhopalurus princeps scorpion per the agreement signed with the Ministry of Environment and Natural Resources of the Dominican Republic.
About Medolife:
Medolife Rx, Inc. is a Wyoming corporation, founded by Dr. Arthur Mikaelian, a pioneer of polarization technology, which has been awarded U.S. Patent 8,097,284 B2 as it pertains to Polarized Scorpion Venom solution and the method for making it. Dr. Mikaelian's technical education began at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological Psychology; he then went on to complete his post-doctorate work at Vernadsky. He also earned an MBA from the University of Bologna in Italy. You can find more about Medolife at: http://medolife.com/
About Quanta:
Quanta, Inc. ("Quanta") utilizes a cutting-edge technology platform that applies advances in quantum biology to increase the potency of active ingredients. Currently, Quanta supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste and facilitate healthier, more sustainable consumption.
The established resonance theory behind polarization process used by Quanta has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Quanta has the opportunity to upend how commercial products are made and the benefits from them. Already, we see multitrillion dollar global industries benefiting from the technology used by Quanta. You can find more about Quanta at: https://buyquanta.com/.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
Phil Sands
https://ir.buyquanta.com/
818-659-8052
SOURCE: QUANTA, INC.
Successful in Treating COVID-19 Patients
Medolife's Therapeutic Scorpion Peptide Proves Successful in Treating COVID-19 Patients in Dominican Republic Study
Updated Wed, January 27, 2021, 6:03 AM
BURBANK, CA / ACCESSWIRE / January 27, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA) today announced In a recent study, a total of 400 patients in the Dominican Republic - where, a majority tested positive for COVID-19, and a small portion were COVID-19 symptomatic even though they tested negative for COVID-19 - reported a 100 percent improvement in symptoms after being administered Escozine®. Many of the patients participating in the study reported severe COVID-19 symptoms, such as difficulty breathing, pain and high fever, which Escozine® was able to relieve within 5 days of treatment. Even patients under ventilators were discharged within days, thanks to this novel product. Located in Santo Domingo, Dominican Republic, The Cruz Jiminian Clinic has carried out this ongoing study since August 2020, and has reported 0 COVID-19 related deaths after the clinic began administering Escozine®. Escozine®, produced by Medolife Rx, Inc., ("Medolife"), is a therapeutic consisting of small molecule peptides derived from a specific species of scorpions, Rhopalurus princeps, endemic to the Dominican Republic. After the successful study, Escozine® is on fast-track to be registered with the Ministry of Health in the Dominican Republic in Q1 2021. Medolife also submitted the study data to the US FDA, which is currently under review for permission to repeat the clinical trial in the United States. In addition to supporting the recovery of COVID-19 patients, Escozine® was registered and certified for cancer treatment by the Ministry of Health in the Dominican Republic in 2010.
"The data proving the efficacy that Escozine has on a multitude of improved patient parameters is consistent with the rapid symptom relief I experienced while on site," said Dr. Annabelle Morgan, Cell and Developmental Biologist and one of Medolife's leading scientists. She noted, "What is even more astonishing is that 100% of patients tested negative for COVID-19 within 5-10 days of treatment."
"More importantly, all COVID-19 healthcare workers, including physicians and nurses, who took Escozine as a preventative, never tested positive" said Dr. Khalid Matalka, another leading scientist at Medolife, specializing in Cancer Therapy and Immunology. "The clinical trial results indicate that Escozine could be used as monotherapy or in combination with standard therapies against COVID-19, which will accelerate the healing from the virus. Besides, observations revealed that Escozine could be used as prevention from the COVID-19 infection."
Scorpion Venom Most Expensive Liquid in the World
From treating cancer to pain management to fighting viral infections, this unique peptide has a vast range of therapeutic applications. In the last decade, a growing interest from Big Pharma companies has caused an increase in the liquid's value: costing $39 million per gallon.
Medolife's Dominican Republic Scorpion Reservation is one of the largest breeding grounds for scorpions on earth. Combined with the company's more than 15 years of research, Medolife is positioned to continue developing groundbreaking formulas and pharmaceutical-grade medications for consumer use.
Pharma's Growing Interest in Scorpion Peptide-Based Therapeutics
Venom has been studied for therapeutic uses for decades. In 2015, the European FP7 Venomics Project studied over 200 animal species worldwide for venom-to-drug development.
Currently, six peptide drugs on the market are derived from venoms, and the pharmaceutical industry has demonstrated a growing interest in these naturally derived therapeutics. The first venom-derived drug, Captopril, was developed by Bristol-Myers Squibb. The drug, derived from snake venom, was approved for use in the 1980s to treat high blood pressure.
Snail venom was used in the development of Prialt®, which is used to treat pain. Also, Byetta®, used to treat type 2 diabetes, was derived from a lizard.
How Venom-Based Drugs Work
The Rhopalurus princeps venom contains a small molecular peptide that can pass through the blood-brain barrier in the body. Four small molecular peptides in the venom can attack various diseases in humans. To do this, it blocks small-conductance chloride, sodium, potassium and calcium ion channels, and it also binds preferentially to abnormal and cancerous cells, leaving the normal cells intact. Medolife holds exclusive rights to the Rhopalurus princeps scorpion per the agreement signed with the Ministry of Environment and Natural Resources of the Dominican Republic.
About Medolife:
Medolife Rx, Inc. is a Wyoming corporation, founded by Dr. Arthur Mikaelian, a pioneer of polarization technology, which has been awarded U.S. Patent 8,097,284 B2 as it pertains to Polarized Scorpion Venom solution and the method for making it. Dr. Mikaelian's technical education began at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological Psychology; he then went on to complete his post-doctorate work at Vernadsky. He also earned an MBA from the University of Bologna in Italy. You can find more about Medolife at: http://medolife.com/
About Quanta:
Quanta, Inc. ("Quanta") utilizes a cutting-edge technology platform that applies advances in quantum biology to increase the potency of active ingredients. Currently, Quanta supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste and facilitate healthier, more sustainable consumption.
The established resonance theory behind polarization process used by Quanta has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Quanta has the opportunity to upend how commercial products are made and the benefits from them. Already, we see multitrillion dollar global industries benefiting from the technology used by Quanta. You can find more about Quanta at: https://buyquanta.com/.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
Phil Sands
https://ir.buyquanta.com/
818-659-8052
SOURCE: QUANTA, INC.
Successful in Treating COVID-19 Patients
Medolife's Therapeutic Scorpion Peptide Proves Successful in Treating COVID-19 Patients in Dominican Republic Study
Updated Wed, January 27, 2021, 6:03 AM
BURBANK, CA / ACCESSWIRE / January 27, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA) today announced In a recent study, a total of 400 patients in the Dominican Republic - where, a majority tested positive for COVID-19, and a small portion were COVID-19 symptomatic even though they tested negative for COVID-19 - reported a 100 percent improvement in symptoms after being administered Escozine®. Many of the patients participating in the study reported severe COVID-19 symptoms, such as difficulty breathing, pain and high fever, which Escozine® was able to relieve within 5 days of treatment. Even patients under ventilators were discharged within days, thanks to this novel product. Located in Santo Domingo, Dominican Republic, The Cruz Jiminian Clinic has carried out this ongoing study since August 2020, and has reported 0 COVID-19 related deaths after the clinic began administering Escozine®. Escozine®, produced by Medolife Rx, Inc., ("Medolife"), is a therapeutic consisting of small molecule peptides derived from a specific species of scorpions, Rhopalurus princeps, endemic to the Dominican Republic. After the successful study, Escozine® is on fast-track to be registered with the Ministry of Health in the Dominican Republic in Q1 2021. Medolife also submitted the study data to the US FDA, which is currently under review for permission to repeat the clinical trial in the United States. In addition to supporting the recovery of COVID-19 patients, Escozine® was registered and certified for cancer treatment by the Ministry of Health in the Dominican Republic in 2010.
"The data proving the efficacy that Escozine has on a multitude of improved patient parameters is consistent with the rapid symptom relief I experienced while on site," said Dr. Annabelle Morgan, Cell and Developmental Biologist and one of Medolife's leading scientists. She noted, "What is even more astonishing is that 100% of patients tested negative for COVID-19 within 5-10 days of treatment."
"More importantly, all COVID-19 healthcare workers, including physicians and nurses, who took Escozine as a preventative, never tested positive" said Dr. Khalid Matalka, another leading scientist at Medolife, specializing in Cancer Therapy and Immunology. "The clinical trial results indicate that Escozine could be used as monotherapy or in combination with standard therapies against COVID-19, which will accelerate the healing from the virus. Besides, observations revealed that Escozine could be used as prevention from the COVID-19 infection."
Scorpion Venom Most Expensive Liquid in the World
From treating cancer to pain management to fighting viral infections, this unique peptide has a vast range of therapeutic applications. In the last decade, a growing interest from Big Pharma companies has caused an increase in the liquid's value: costing $39 million per gallon.
Medolife's Dominican Republic Scorpion Reservation is one of the largest breeding grounds for scorpions on earth. Combined with the company's more than 15 years of research, Medolife is positioned to continue developing groundbreaking formulas and pharmaceutical-grade medications for consumer use.
Pharma's Growing Interest in Scorpion Peptide-Based Therapeutics
Venom has been studied for therapeutic uses for decades. In 2015, the European FP7 Venomics Project studied over 200 animal species worldwide for venom-to-drug development.
Currently, six peptide drugs on the market are derived from venoms, and the pharmaceutical industry has demonstrated a growing interest in these naturally derived therapeutics. The first venom-derived drug, Captopril, was developed by Bristol-Myers Squibb. The drug, derived from snake venom, was approved for use in the 1980s to treat high blood pressure.
Snail venom was used in the development of Prialt®, which is used to treat pain. Also, Byetta®, used to treat type 2 diabetes, was derived from a lizard.
How Venom-Based Drugs Work
The Rhopalurus princeps venom contains a small molecular peptide that can pass through the blood-brain barrier in the body. Four small molecular peptides in the venom can attack various diseases in humans. To do this, it blocks small-conductance chloride, sodium, potassium and calcium ion channels, and it also binds preferentially to abnormal and cancerous cells, leaving the normal cells intact. Medolife holds exclusive rights to the Rhopalurus princeps scorpion per the agreement signed with the Ministry of Environment and Natural Resources of the Dominican Republic.
About Medolife:
Medolife Rx, Inc. is a Wyoming corporation, founded by Dr. Arthur Mikaelian, a pioneer of polarization technology, which has been awarded U.S. Patent 8,097,284 B2 as it pertains to Polarized Scorpion Venom solution and the method for making it. Dr. Mikaelian's technical education began at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological Psychology; he then went on to complete his post-doctorate work at Vernadsky. He also earned an MBA from the University of Bologna in Italy. You can find more about Medolife at: http://medolife.com/
About Quanta:
Quanta, Inc. ("Quanta") utilizes a cutting-edge technology platform that applies advances in quantum biology to increase the potency of active ingredients. Currently, Quanta supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste and facilitate healthier, more sustainable consumption.
The established resonance theory behind polarization process used by Quanta has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Quanta has the opportunity to upend how commercial products are made and the benefits from them. Already, we see multitrillion dollar global industries benefiting from the technology used by Quanta. You can find more about Quanta at: https://buyquanta.com/.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
Phil Sands
https://ir.buyquanta.com/
818-659-8052
SOURCE: QUANTA, INC.
Not sure if it is dilution as the worry here:
Section 4. Conversion.
a) Voluntary Conversion. At any time after the Original Issue Date until this Debenture is no longer outstanding, this Debenture shall be convertible, in whole or in part, into shares of Common Stock at the option of the Holder, at any time and from time to time (subject to the conversion limitations set forth in Section 4(d) hereof). The Holder shall effect conversions by delivering to the Company a Notice of Conversion, the form of which is attached hereto as Annex A (each, a “Notice of Conversion”), specifying therein the principal amount of this Debenture to be converted and the date on which such conversion shall be effected (such date, the “Conversion Date”). If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion is deemed delivered hereunder. No ink-original Notice of Conversion shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required. To effect conversions hereunder, the Holder shall not be required to physically surrender this Debenture to the Company unless the entire principal amount of this Debenture has been so converted in which case the Holder shall surrender this Debenture as promptly as is reasonably practicable after such conversion without delaying the Company’s obligation to deliver the shares on the Share Delivery Date. Conversions hereunder shall have the effect of lowering the outstanding principal amount of this Debenture in an amount equal to the applicable conversion. The Holder and the Company shall maintain records showing the principal amount(s) converted and the date of such conversion(s). The Company may deliver an objection to any Notice of Conversion within one (1) Business Day of delivery of such Notice of Conversion. In the event of any dispute or discrepancy, the records of the Holder shall be controlling and determinative in the absence of manifest error. The Holder, and any assignee by acceptance of this Debenture, acknowledge and agree that, by reason of the provisions of this paragraph, following conversion of a portion of this Debenture, the unpaid and unconverted principal amount of this Debenture may be less than the amount stated on the face hereof.
b) Conversion Price. The conversion price in effect on any Conversion Date shall be equal to the lesser of (i) $0.33 (“Set Conversion Price”) and (ii) 85% of the lowest VWAP during the five Trading Days immediately prior to the Conversion Date, subject to adjustment herein (the “Conversion Price”).
c) Mechanics of Conversion.
i. Conversion Shares Issuable Upon Conversion of Principal Amount. The number of Conversion Shares issuable upon a conversion hereunder shall be determined by the quotient obtained by dividing (x) the outstanding principal amount of this Debenture to be converted by (y) the Conversion Price.
ii. Delivery of Conversion Shares Upon Conversion. Not later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) after each Conversion Date (the “Share Delivery Date”), the Company shall deliver, or cause to be delivered, to the Holder (A) the Conversion Shares which, on or after the earlier of (i) the six month anniversary of the Original Issue Date or (ii) the Effective Date, shall be free of restrictive legends and trading restrictions
Why is it? You get the cream of the penny pickers all gathered on the moderator side of this one and not one of them fills in the I-box...
Can you read between the lines here?